What predicts response to sertraline for people with depression in primary care? a secondary data analysis of moderators in the PANDA trial

PLoS One. 2024 May 9;19(5):e0300366. doi: 10.1371/journal.pone.0300366. eCollection 2024.

Abstract

Purpose: Antidepressants are a first-line treatment for depression, yet many patients do not respond. There is a need to understand which patients have greater treatment response but there is little research on patient characteristics that moderate the effectiveness of antidepressants. This study examined potential moderators of response to antidepressant treatment.

Methods: The PANDA trial investigated the clinical effectiveness of sertraline (n = 326) compared with placebo (n = 329) in primary care patients with depressive symptoms. We investigated 11 potential moderators of treatment effect (age, employment, suicidal ideation, marital status, financial difficulty, education, social support, family history of depression, life events, health and past antidepressant use). Using multiple linear regression, we investigated the appropriate interaction term for each of these potential moderators with treatment as allocated.

Results: Family history of depression was the only variable with weak evidence of effect modification (p-value for interaction = 0.048), such that those with no family history of depression may have greater benefit from antidepressant treatment. We found no evidence of effect modification (p-value for interactions≥0.29) by any of the other ten variables.

Conclusion: Evidence for treatment moderators was extremely limited, supporting an approach of continuing discuss antidepressant treatment with all patients presenting with moderate to severe depressive symptoms.

Publication types

  • Research Support, Non-U.S. Gov't
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antidepressive Agents* / therapeutic use
  • Data Analysis
  • Depression* / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Primary Health Care*
  • Secondary Data Analysis
  • Sertraline* / therapeutic use
  • Treatment Outcome

Substances

  • Sertraline
  • Antidepressive Agents

Grants and funding

The PANDA trial is independent research commissioned by the National Institute for Health Research (NIHR) Programme Grant for Applied Research (RP-PG-0610-10048) [https://www.nihr.ac.uk/explore-nihr/funding-programmes/programme-grants-for-applied-research.htm] awarded to GlL, NW, SG, TJP and RA.The views expressed in this publication are those of the author(s) and not necessarily those of the sponsor, UK National Health Service, NIHR, or UK Department of Health and Social Care. CA is funded on a Bristol, North Somerset and South Gloucestershire ICB launching fellowship (RCF 21/22-3.1) [https://bnssg.icb.nhs.uk/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.